Hypothesis

Sustained nuclear localization of ERK1/2 in peripheral nociceptive neurons promotes a senescent phenotype that heightens pain sensitivity and mirrors epigenetic age acceleration. Restoring cytoplasmic ERK1/2 signaling reverses both the pain phenotype and epigenetic aging markers.

Mechanistic Rationale

• ERK shuttling determines cell fate: Transient ERK activity supports proliferation, whereas sustained nuclear ERK drives senescence via p21 upregulation and SASP secretion (IL‑6, IL‑8) {1} {2}. Nuclear import relies on dual phosphorylation and importin‑7, while export is mediated by PEA‑15 and phosphatases such as DUSP6/7 (cytoplasmic) and DUSP1/4/5 (nuclear) {3}.
• Aging impairs shuttling: Aged tissues show dysregulated phosphatase activity and Caveolin‑1‑mediated phosphatase inhibition, favoring nuclear retention {3}. In sensory neurons, this shift could convert ERK from a survival signal to a senescence trigger.
• Senescent nociceptors sensitize pain: Senescent fibroblasts and glia release SASP factors that lower activation thresholds of nearby neurons. A similar autocrine/paracrine loop in nociceptors would increase spontaneous firing and reduce pain tolerance, aligning with observed age‑related hyperalgesia {5} {6}.
• Pain tolerance predicts epigenetic age: Lower heat‑pain thresholds correlate with younger DNAm age in twins, indicating that pain perception reflects biological aging beyond chronological years {4}.

Thus, nuclear ERK1/2 accumulation in nociceptors provides a mechanistic bridge linking cellular senescence to the pain‑based biomarker of biological age.

Testable Predictions

1. In aged mice, dorsal root ganglion (DRG) neurons will show increased nuclear ERK1/2 relative to cytoplasmic ERK1/2 compared with young mice, detectable by subcellular fractionation or proximity ligation assay.
2. Higher nuclear ERK1/2 will correlate with lowered pain thresholds (hot‑plate latency, von Freye filament force) and elevated senescence markers (p21, SA‑β‑gal, SASP cytokines IL‑6, IL‑8) in the same DRG samples.
3. Genetic or pharmacological forced cytoplasmic retention of ERK1/2 (e.g., DRG‑specific overexpression of wild‑type PEA‑15 or shRNA against importin‑7) will normalize pain sensitivity and reduce senescence markers in aged mice.
4. Rescue of cytoplasmic ERK will attenuate epigenetic age acceleration measured by a mouse DNAm clock or by reduced p16Ink4a expression in DRG tissue.
5. Conversely, enhancing nuclear ERK in young mice (via constitutively active MEK1 or PEA‑15 knockdown) will prematurely lower pain thresholds and increase epigenetic age markers.

Experimental Design (Outline)

• Animals: Young (3 mo) and aged (24 mo) C57BL/6 mice; subsets with sensory‑neuron‑specific Cre drivers (Advillin‑Cre or Nav1.8‑Cre) crossed to floxed PEA‑15 or importin‑7 alleles; AAV‑mediated shRNA or overexpression vectors for acute manipulation.
• Readouts:
  • Subcellular ERK1/2 levels (Western blot of nuclear/cytoplasmic fractions, immunofluorescence quantification).
  • Pain behavior: hot‑plate test (latency to lick/paw), von Freye filaments (50 % withdrawal threshold), acetone spray for cold allodynia.
  • Senescence: p21 Western, SA‑β‑gal staining, ELISA for IL‑6/IL‑8 in DRG lysates.
  • Epigenetic age: Mouse epigenetic clock (e.g., based on CpG sites from [Pedretti et al., 2022]) or p16Ink4a qPCR as a surrogate.
• Analysis: Compare nuclear/cytoplasmic ERK ratios across age and manipulation groups; perform regression analysis linking ERK localization to pain thresholds and epigenetic age; test causality via rescue experiments.

Falsifiability

If nuclear ERK1/2 accumulation in DRG neurons does not differ between young and old animals, or if altering ERK localization fails to produce predictable changes in pain sensitivity and epigenetic age markers, the hypothesis would be refuted. Likewise, if forced cytoplasmic ERK in aged mice normalizes senescence markers without affecting pain behavior, the proposed nociceptor‑centric mechanism would be insufficient.

Potential Impact

Confirming this link would establish a peripheral signaling node that couples cellular senescence to a functional, easily assayed biomarker of biological age. It would also suggest that targeting ERK shuttling—already druggable with MEK inhibitors or PEA‑15 mimetics—could ameliorate age‑related pain and possibly retard broader aging phenotypes.